CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Anbogen Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Anbogen Therapeutics Inc
Phone: +886 289798616p:+886 289798616 TAIPEI, 115  Taiwan Ticker: 77847784
Business Summary
Anbogen Therapeutics Inc is a Taiwan-based company mainly engaged in the development and sales of precision medicine drugs for cancer. Its products include ABT-301 and ABT-101. ABT-301 is a small-molecule oral drug, a pan-histone deacetylase inhibitor, which has the function of regulating the cancer immune environment. ABT-101 is an oral, irreversible, selective tyrosine kinase inhibitor that effectively inhibits the growth of cells with epidermal growth factor receptor (EGFR) mutations, or those exhibiting overexpression and activating mutations of human epidermal growth factor receptor 2 (HER2 or ERBB2).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Operating Officer, General Manager JoeHsueh
Chief Executive Officer, Founder, CSO Tsu-AnHsu
Vice President - Finance and Accounting EndyYang
Vice President - Clinical Strategy Kien-ThiamTan 1/1/2022 1/1/2022
Vice President - Business Development Angus Tsung-KaiWu

General Information
Number of Employees: 42 (As of 12/31/2025)
Outstanding Shares: 187,601,488 (As of 5/5/2026)
Stock Exchange: TPO
Fax Number: +886 227645999


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, May 16, 2026